Ranbaxy Pharma

8/8/2019 Ranbaxy Pharma

1/26

Ranbaxy Laboratories

LimitedTo become a Research based International

Pharmaceutical Company

Submitted By-:

Anand Kumar Singh S-03

Pankaj Kumar Jha S-13

Sandeep Kr Sharma S-20

Prabhat Kumar S-15


2/26

INTRODUCTION

Type: Public (BSE: 500359) Industry :Pharmaceutical

Founded :1961

Headquarters: Gurgaon, Haryana, India

Products :Pharmaceuticals and diagnostics

Employees :1100 in R&D

Website: www.ranbaxy.com


3/26

Company profile

Ranbaxy Laboratories Limited (Ranbaxy),India's largestpharmaceutical company.

Ranbaxy was started by Ranbir Singh and Gurbax Singh in1937

Ranbaxy was incorporated in 1961 and went public in1973.

Ranbaxy today has a presence in 23 of the top 25pharmaceutical markets of the world.


4/26

Contd..

For the year 2009, the Company recorded GlobalSales of US $ 1519 Mn.

In 2009, North America, the Company's largest

market contributed sales of US $ 397 Mn, followedby Europe garnering US $ 269 Mn and Asiaclocking sales of around US $ 441 Mn.

In June 2008, Ranbaxy entered into an alliance

with one of the largest Japanese innovatorcompanies, Daiichi Sankyo Company Ltd.,


5/26

Management team

Founder: Ranbir Singh and Gurbax Singh

Chairman : Dr. Tsutomu Une

M.D.+C.E.O. : Mr. Atul SobtiExpected C.E.O. :Malvinder Mohan Singh

President (R&d): Dr. Sudershan K. Arora


6/26

Product profileValacyclovir

SimvastatinCo-Amoxyclav

Ciprofloxacin and Combinations

Amoxycillin and Combinations

Isotretinoin

Ketorolac Tromethamine

Loratadine and Combinations

Ginseng+Vitamins Cephalexin

Atorvastatin and Combinations


7/26

The India Pharma Story Davos 2006

Source Financial Times


8/26

India in Global Generics

% Share of USA DMF filings

India China

2004 27% 9%

2005 37% 10%

2006 44% 14%

Q406 47% 9%

Source: US FDA / J P Morgan Research

FDA Approved

Plants in India

Highest No

of DMF filings


9/26

0

40

80

120

160

2002 2003 2004 2005

ANDA Filings in USA by Indian Companies

24

46

64

144

One in every four ANDAs filed by Indian Companies in top US FDA filers(Source: KPMG)

No Chinese generic company has yet filed a US FDA ANDA but expected

in 2008

India in Global Generics


10/26

Ranbaxy Today

Amongst Top 10 Global Gx companies

Ground presence in 49 countries,

products sold in > 125

International business ~ 80% of sales

Manufacturing locations in 11 countries

> 11,000 employees, 51 nationalities

Strong Generics & Innovative researchcapabilities

2 0 0 1 2 0 0 3 2 0 0 6

$ 553

$ 972

$ 1339

CAGR

19%

Global Sales

Worldwide Presence


11/26


12/26

Increasing Focus on Costs

* Estimate, ^ Bio-Analytical / Bio - Equivalence

2005 2008*

Increasing sourcing from low costcountries .i.e. India & China

Improving R&D cost efficiencies

Optimizing SG&A cost structures

65% 80%35%20%

2006 2005

In-House 71% 28%

Overseas CRO 8% 61%

Indian CRO 21% 11%

% Bio-Studies (BA/BE^) conducted

2006 2005

Sales growth +17%

SGA growth - Nil

Advanced Markets Low Cost Countries


13/26

Geographic Sales Split - 2006

Asia

$367, +19

A m er i cas

$440, +18

Europe$332, +23

Africa

$85, +24

* Including CIS, RoW Rest of the World

Global Sales 2006 (US$ Mn)

DF 1224 +20%

API 115 - 9%

Total 1339 + 17%

Sales 2006 Dosage Forms US$ 1224 Mn

Key New Markets Canada, Spain, Italy, Australia & Japan

33%

25%27%

6%


14/26

Geographic Sales Split Q1 2007

Asia

$367, +19

Amer i ca

$440, +18

Europe$332, +23

Africa

$85, +24

* Including CIS, RoW Rest of the World

Global Sales Q1 2007 (US$ Mn)

DF 332 +30%

API 23 - 25%

Total 355 + 24%

Sales Q1 2007 Dosage Forms US$ 332 Mn

29%

31%27%

7%


15/26

USA

Products pending approval

Source: Merrill Lynch Equity Research, February 2007

0

40

80

120

160

200

Teva Ranbaxy Sun Mylan Watson DRL Barr Par

#ofAND

As

Second largestpipeline


16/26

Potential FTF Challenges

0

9

18

27

36

45

Teva

Ranb

axy

DRL

Mylan

Watson

Barr Pa

rSu

n

#ofFTFs

Second largestFTF pipeline

Source: Merrill Lynch Equity Research, February 2007

USA


17/26

European Union

Presence in 23 of the 27 EU countries

Regulatory changes & price impacted

Western European markets

Strong product flow in 07 with

multiple Day 1s

Major countries

- Germany : AOK business

- France : Supplies from India

- UK : Gabapentin launch

RoE to maintain growth momentum

0

5 0

1 0 0

1 5 0

2 0 0

2 5 0

3 0 0

2 0 0 6 2 0 0 5

Sales

$ 267

$ 214

$ Mn

Romania


18/26

India

Fastest growing Company in India on MAT basis

(Source :ORG-IMS Mat Mar 2007)

65 new products introduced in 2006

No 1 NDDS Company with 8% MS. Contribution to total sales ~ 9%

Dedicated task forces for Specialized & Chronic therapies

Chronic share contribution at 21% (2005 : 20%)

21 brands in Top 300 of Industry ( 2005 :19)

First to market 10

NDDS 6

In-licensed 8

Source : ORG IMS Audit Nov 2006, Moving Quarter Basis

GSK

Cipla

Ranbaxy

5.0%

4.9%

5.1%

Source : IMS - ORG


19/26

Research & Development

New R&D facility for Drug

Discovery Research (DDR)

R&D I

R&D III

R&D II R&D IV


20/26

Research & Development

Dedicated Facilities for Innovative & Generics Research

> 1400 R&D Personnel ( ~ 250 PhDs)

8 - 10 NCE molecules in pipeline

NDDS based products ( 4 platform technologies)R&D collaborations

Alliance /

Collaboration in

DDR

Out-licensing

in NDDS

Out-licensing

in DDR


21/26

Ranbaxy GSK Collaboration

Expansion of strategic alliance established in 2003

Take leads beyond candidate selection to POC* in man

Therapeutic area focus of AI, Metabolic, Anti-inflammatory

and Oncology

> US$ 100 mn in milestone payments and double digit

royalties on commercialization of a product

Co- marketing rights in India

First candidate identified for Respiratory Inflammation

Proof of Concept


22/26

Recent Acquisitions & Alliances

Terapia (Romania)

Be-Tabs (South Africa)

Allen (Italy)

Ethimed (Belgium)

Mundogen (Spain)

Zenotech (India)

Krebs (India)

Jupiter Biosciences*(Ind.)

Cardinal Drugs (India)

Auto-injector Tech.(USA)

* Subject to due diligence
http://images.google.co.in/imgres?imgurl=www.psconsortium.net/Images/alliances.jpg&imgrefurl=http://www.psconsortium.net/Alliances.html&h=200&w=320&prev=/images%3Fq%3Dalliances%2B%26start%3D40%26svnum%3D10%26hl%3Den%26lr%3D%26ie%3DUTF-8%26oe%3DUTF-8%26sa%3DN


23/26

Niche Alliances

Increasing focus on chronic / lifestyle diseases segment

High entry barriers - technology & resource intensive

Fermentation

based products

Bio-similars &

Oncologics

Peptides

KrebsZenotech Jupiter*

* Subject to due diligence


24/26

Financials

Particulars

Sales

EBITDA

% sales

OPBT*

PBT

PAT

* 2005 sales excludes sales from discontinued operations .i.e Allied Businesses. OPBT Operating profit before tax

Figures in US$ Mn

Q1 2007 %

355 24%

43

12%

35%

36 102%

37 94%

29 81%

2006 %

1339 17%

207

16%

144%

131 481%

144

226%

114 90%


25/26

In Summary

A strong 2006 performance on all parameters

Buoyant performance across key geographies

Continuing focus on cost optimization

Robust product flow

Growth through organic & inorganic

Discovery pipeline progressing well

Global Generic rank 9th / 10th


26/26

Thank You

Ranbaxy Pharma

Documents